AU2002219175A1 - Crystalline forms of cerivastatin sodium - Google Patents

Crystalline forms of cerivastatin sodium

Info

Publication number
AU2002219175A1
AU2002219175A1 AU2002219175A AU1917502A AU2002219175A1 AU 2002219175 A1 AU2002219175 A1 AU 2002219175A1 AU 2002219175 A AU2002219175 A AU 2002219175A AU 1917502 A AU1917502 A AU 1917502A AU 2002219175 A1 AU2002219175 A1 AU 2002219175A1
Authority
AU
Australia
Prior art keywords
crystalline forms
cerivastatin sodium
cerivastatin
sodium
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002219175A
Inventor
Fritz Blatter
Nicole End
Martin Szelagiewicz
Paul Adriaan Van Der Schaaf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Spezialitaetenchemie Holding AG
Ciba SC Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Spezialitaetenchemie Holding AG, Ciba SC Holding AG filed Critical Ciba Spezialitaetenchemie Holding AG
Publication of AU2002219175A1 publication Critical patent/AU2002219175A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002219175A 2000-12-21 2001-12-12 Crystalline forms of cerivastatin sodium Abandoned AU2002219175A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00811225 2000-12-21
EP00811225 2000-12-21
PCT/EP2001/014602 WO2002050036A1 (en) 2000-12-21 2001-12-12 Crystalline forms of cerivastatin sodium

Publications (1)

Publication Number Publication Date
AU2002219175A1 true AU2002219175A1 (en) 2002-07-01

Family

ID=8175095

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002219175A Abandoned AU2002219175A1 (en) 2000-12-21 2001-12-12 Crystalline forms of cerivastatin sodium

Country Status (4)

Country Link
US (1) US20040063961A1 (en)
EP (1) EP1345903A1 (en)
AU (1) AU2002219175A1 (en)
WO (1) WO2002050036A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006500337A (en) * 2002-07-26 2006-01-05 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド Polymorphic and amorphous forms of benazepril hydrochloride
JP5192147B2 (en) * 2003-02-12 2013-05-08 日産化学工業株式会社 Crystalline form of pitavastatin calcium
EP2001887B1 (en) 2006-04-06 2010-09-15 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
EP2007377A4 (en) 2006-04-06 2011-08-17 Glaxo Group Ltd Antibacterial agents
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
AR065670A1 (en) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS
SI2137196T1 (en) * 2007-04-20 2011-01-31 Glaxo Group Ltd Glaxo Welcome House Tricyclic nitrogen containing compounds as antibacterial agents
EP2080761A1 (en) 2008-01-18 2009-07-22 Glaxo Group Limited Compounds
EP2352734A1 (en) 2008-10-17 2011-08-10 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials
JP5653935B2 (en) 2009-01-15 2015-01-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Naphthyridin-2 (1H) -one compounds useful as antibacterial agents
AR101674A1 (en) 2014-08-22 2017-01-04 Glaxosmithkline Ip Dev Ltd USE OF A TRICYCLIC COMPOUND CONTAINING NITROGEN
TW201722965A (en) 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 Compounds for use in antibacterial applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
DE4309553A1 (en) * 1993-03-24 1994-09-29 Bayer Ag Process for the preparation of 3R, 5S - (+) - sodium erythro- (E) -7- (4- (4-flurophenyl) -2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl) -3, 5-dihydroxy-hept-6-enoate
US6531507B1 (en) * 2000-06-09 2003-03-11 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same

Also Published As

Publication number Publication date
US20040063961A1 (en) 2004-04-01
EP1345903A1 (en) 2003-09-24
WO2002050036A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
AU2002363005A1 (en) Derivatives of uk-2a
IL159861A0 (en) Crystalline forms of fluvastatin sodium
AU2001266345A1 (en) Five-membered-ring compound
AU2002330453A1 (en) Crystals of hydroxynorephedrine derivative
AU2002219175A1 (en) Crystalline forms of cerivastatin sodium
AU2001285325A1 (en) Use of threo-methylphenidate compounds to enhance memory
AU2001244692A1 (en) Novel crystal form of pyrrolidylthiocarbapenem derivative
AU2001269685A1 (en) Crystallization of 4-diphosphocytidyl-2-c-methylerythritol synthesis
AU2002217071A1 (en) Novel use of polyhydroxy compounds
AU2001288092A1 (en) Method of crystallization
AU2001284763A1 (en) Preparation of risperidone
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2982000A (en) Preparation of 9-hydrocarbyl-9-phosphabicyclononanes
AU5029801A (en) Copolymers of allylphosphonium salts
AU2001245950A1 (en) Preparation of deoxynucleosides
AU2001272490A1 (en) Use of galiella lactone
AU2001288484A1 (en) Novel metallotexaphyrin derivatives
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AU2002216038A1 (en) Preparation of monofluoroalkenes
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2002216043A1 (en) Compounds
AU3376501A (en) Improvement of implantation rate
AU2001263789A1 (en) Crystalline alkycycline derivative
AU2002345602A1 (en) Crystalline salts of benzoylbenzofuran-derivatives
AU2001259381A1 (en) Synthesis of diphosphinoarenes